Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
Stopped Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee.
Conditions
- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Primary Peritoneal Cancer
Interventions
- DRUG: Niraparib
- DRUG: Dostarlimab
Sponsor
AGO Research GmbH
Collaborators